Identifying patients at high risk of heparin-induced thrombocytopenia-associated thrombosis with a platelet activation assay using flow cytometry
Authors:
- 14 November 2017
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 117 (01) , 127-138
Abstract
Summary: To diagnose heparin-induced thrombocytopenia (HIT), detection of platelet-activating antibodies (HIT antibodies) is crucial. However, serum platelet activation profiles vary across patients and depend on test conditions. We evaluated the association between clinical outcomes and platelet-activating profiles assessed by a platelet microparticle assay (PMA), which detects activation of washed platelets induced by HIT antibodies, in 401 consecutive patients clinically suspected of having HIT. We made modifications to the assay, such as donor selection for washed platelets that increased sensitivity. Serum that activated platelets at a therapeutic (but not high) heparin concentration was defined as positive. Of these, serum that activated platelets within 30 minutes or in the absence of heparin was defined as strongly positive. The remaining samples were considered weakly positive. As a result, 97 % and 93 % of patients who tested strongly and weakly positive had clinical profiles consistent with HIT, respectively. The incidence of thromboembolic events (TEEs) after heparin exposure in patients who tested strongly positive, weakly positive, and negative was 61 %, 40 %, and 29 %, respectively. Among patients who did not experience a TEE on the day HIT was suspected, there was no significant difference in the cumulative incidence of subsequent TEEs between patients who tested strongly and weakly positive when argatroban was initiated on the same day (19.0 % vs 7.1 %, p=0.313), but there was a significant difference when argatroban therapy was delayed by one or more days (61.1 % vs 17.6 %, p=0.007). The modified PMA is effective in diagnosing HIT and identifying patients at high risk for HIT-associated TEEs.Supplementary Material to this article is available online at www.thrombosis-online.com.Keywords
Funding Information
- Health and Labour Sciences Research (27–1–2)
This publication has 42 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Murine Monoclonal Antibody to Platelet Factor 4/Heparin Complexes as a Potential Reference Standard for Platelet Activation Assays in Heparin-Induced ThrombocytopeniaClinical and Applied Thrombosis/Hemostasis, 2012
- PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRIBlood, 2012
- Treatment and Prevention of Heparin-Induced ThrombocytopeniaChest, 2012
- Prospective multicentre cohort study of heparin-induced thrombocytopenia in acute ischaemic stroke patientsBritish Journal of Haematology, 2011
- Non‐necrotizing heparin‐induced skin lesions and the 4T’s scoreJournal of Thrombosis and Haemostasis, 2010
- Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT AntibodiesArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongationThrombosis and Haemostasis, 2005
- A diagnostic test for heparin‐induced thrombocytopenia: detection of platelet microparticles using flow cytometryBritish Journal of Haematology, 1996
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995